Bcl-2 expression is altered with ovarian tumor progression: An immunohistochemical evaluation

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Anderson, Nicole S ^a   Turner, Leslie ^a   Livingston, Sandra ^a   Chen, Ren ^b   Nicosia, Santo V ^a,c   Kruk, Patricia A ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ADULT; ARTICLE; BENIGN TUMOR; CANCER STAGING; CELLULAR DISTRIBUTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TISSUE SECTION; TUMOR GROWTH;

EID: 77952250738     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-16     Document Type: Article

References (43)

1. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 2 71 96 10.3322/CA.2007.0010 18287387
2. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. TI Williams KL Toups DA Saggese KR Kalli WA Cliby DC Muddiman, J Proteome Res 2007 6 8 2936 2962 10.1021/pr070041v 17583933
3. Ovarian carcinogenesis and the biology of ovarian surface epithelium. N Auersperg SL Maines-Bandiera HG Dyck, J Cell Physiol 1997 173 2 261 265 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G 9365533
4. Ovarian carcinogenesis: an alternative hypothesis. JM Piek PJ van Diest RH Verheijen, Adv Exp Med Biol 2008 622 79 87 18546620
5. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. S Salvador B Gilks M Kobel D Huntsman B Rosen D Miller, Int J Gynecol Cancer 2009 19 1 58 64 19258943
6. Neoplasms of the ovarian mesothelium. SV Nicosia RF Nicosia, Pathology of Human Neoplasms New York: Raven Press, Azar HA, 1988
7. Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. N Auersperg IA Maclaren PA Kruk, Biol Reprod 1991 44 4 717 724 10.1095/biolreprod44.4.717 1710511
8. Tumor-stroma interactions. NA Bhowmick HL Moses, Curr Opin Genet Dev 2005 15 1 97 101 10.1016/j.gde.2004.12.003 15661539
9. New highlights on stroma-epithelial interactions in breast cancer. MH Barcellos-Hoff D Medina, Breast Cancer Res 2005 7 1 33 36 10.1186/bcr972 15642180
10. Epithelial-stromal interactions in colon cancer. FT Bosman A de Bruine C Flohil A van der Wurff J ten Kate WW Dinjens, Int J Dev Biol 1993 37 1 203 211 8507562
11. Expression of alpha-smooth-muscle actin in stromal cells of the uterine cervix during epithelial neoplastic changes. M Cintorino E Bellizzi de Marco P Leoncini SA Tripodi LJ Xu AP Sappino A Schmitt-Graff G Gabbiani, Int J Cancer 1991 47 6 843 846 10.1002/ijc.2910470609 2010226
12. Stromal-epithelial interactions in the normal and neoplastic prostate. SW Hayward MA Rosen GR Cunha, Br J Urol 1997 79 Suppl 2 18 26 9126066
13. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. JA Parrott E Nilsson R Mosher G Magrane D Albertson D Pinkel JW Gray MK Skinner, Mol Cell Endocrinol 2001 175 1-2 29 39 10.1016/S0303-7207(01)00436-1 11325514
14. Mesenchymal-epithelial interactions between normal and transformed human bladder cells. TR Pritchett JK Wang PA Jones, Cancer Res 1989 49 10 2750 2754 2713858
15. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. I Skirnisdottir T Seidal E Gerdin B Sorbe, Int J Gynecol Cancer 2002 12 3 265 276 10.1046/j.1525-1438.2002.01121.x 12060448
16. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. S Kondratiev E Sabo E Yakirevich O Lavie MB Resnick, Clin Cancer Res 2004 10 13 4450 4456 10.1158/1078-0432.CCR-0732-3 15240536
17. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. L Zhang JR Conejo-Garcia D Katsaros PA Gimotty M Massobrio G Regnani A Makrigiannakis H Gray K Schlienger MN Liebman,, et al. N Engl J Med 2003 348 3 203 213 10.1056/NEJMoa020177 12529460
18. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. B Clarke AV Tinker CH Lee S Subramanian M van de Rijn D Turbin S Kalloger G Han K Ceballos MG Cadungog,, et al. Mod Pathol 2009 22 3 393 402 10.1038/modpathol.2008.191 19060844
19. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. E Sato SH Olson J Ahn B Bundy H Nishikawa F Qian AA Jungbluth D Frosina S Gnjatic C Ambrosone,, et al. Proc Natl Acad Sci USA 2005 102 51 18538 18543 10.1073/pnas.0509182102 16344461
20. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. J Diebold G Baretton M Felchner W Meier K Dopfer M Schmidt U Lohrs, Am J Clin Pathol 1996 105 3 341 349 8602616
21. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. R Fauvet C Dufournet C Poncelet C Uzan D Hugol E Darai, J Surg Oncol 2005 92 4 337 343 10.1002/jso.20424 16299808
22. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. JJ Herod AG Eliopoulos J Warwick G Niedobitek LS Young DJ Kerr, Cancer Res 1996 56 9 2178 2184 8616869
23. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. WY Chan KK Cheung JO Schorge LW Huang WR Welch DA Bell RS Berkowitz SC Mok, Am J Pathol 2000 156 2 409 417 10666369
24. Expression and prognostic significance of Bcl-2 in ovarian tumours. R Henriksen E Wilander K Oberg, Br J Cancer 1995 72 5 1324 1329 7577491
25. bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. M Marone G Scambia S Mozzetti G Ferrandina S Iacovella A De Pasqua P Benedetti-Panici S Mancuso, Clin Cancer Res 1998 4 2 517 524 9516944
26. The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review). I Zusman P Gurevich E Gurevich H Ben-Hur, Int J Oncol 2001 18 5 965 972 11295042
27. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. M Baekelandt GB Kristensen JM Nesland CG Trope R Holm, J Clin Oncol 1999 17 7 2061 10561259
28. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. NS Anderson Y Bermudez D Badgwell R Chen SV Nicosia RC Bast Jr PA Kruk, Gynecol Oncol 2009 112 1 60 67 10.1016/j.ygyno.2008.09.037 19007973
29. Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. BY Karlan RL Baldwin FD Cirisano PW Mamula J Jones LD Lagasse, Gynecol Oncol 1995 59 1 67 74 10.1006/gyno.1995.1269 7557618
30. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. MH Barcellos-Hoff SA Ravani, Cancer Res 2000 60 5 1254 1260 10728684
31. Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. H Joseph AE Gorska P Sohn HL Moses R Serra, Mol Biol Cell 1999 10 4 1221 1234 10198068
32. Reconstruction of functionally normal and malignant human breast tissues in mice. C Kuperwasser T Chavarria M Wu G Magrane JW Gray L Carey A Richardson RA Weinberg, Proc Natl Acad Sci USA 2004 101 14 4966 4971 10.1073/pnas. 0401064101 15051869
33. Stromal involvement in malignant growth. A van den Hooff, Adv Cancer Res 1988 50 159 196 3287842
34. Morphologic precursors of ovarian epithelial tumors. L Resta S Russo GA Colucci J Prat, Obstet Gynecol 1993 82 2 181 186 8336861
35. Practical Gynecologic Oncology. JS Berek NF Hacker TC Hengst, Philadelphia: Lippincott Williams and Wilkins 4 2004
36. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. SF Adams DA Levine MG Cadungog R Hammond A Facciabene N Olvera SC Rubin J Boyd PA Gimotty G Coukos, Cancer 2009 115 13 2891 2902 10.1002/cncr.24317 19472394
37. Transforming growth factor-beta: an important mediator of immunoregulation. JH Kehrl, Int J Cell Cloning 1991 9 5 438 450 10.1002/stem.1991.5530090502 1955735
38. The role of cytokines in both the normal and malignant ovary. MA Nash G Ferrandina M Gordinier A Loercher RS Freedman, Endocr Relat Cancer 1999 6 1 93 107 10.1677/erc.0.0060093 10732792
39. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. N Ahmed EW Thompson MA Quinn, J Cell Physiol 2007 213 3 581 588 10.1002/jcp.21240 17708542
40. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. AB Roberts MB Sporn RK Assoian JM Smith NS Roche LM Wakefield UI Heine LA Liotta V Falanga JH Kehrl,, et al. Proc Natl Acad Sci USA 1986 83 12 4167 4171 10.1073/pnas.83.12.4167 2424019
41. The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma. A Mueller J O'Rourke P Chu A Chu MF Dixon DM Bouley A Lee S Falkow, Am J Pathol 2005 167 3 797 812 16127158
42. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. BC Sheu WH Kuo RJ Chen SC Huang KJ Chang SN Chow, Breast 2008 17 6 604 610 10.1016/j.breast.2008. 06.001 18656354
43. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. MR Hussein DA Elsers SA Fadel AE Omar, J Clin Pathol 2006 59 3 316 324 10.1136/jcp.2005.028860 16505286